about
Hyperinsulinemia Down-Regulates TLR4 Expression in the Mammalian Heart.Sustained, Low-Intensity Exercise Achieved by a Dynamic Feeding System Decreases Body Fat in Ponies.Hyperinsulinemic laminitis.The equine glucose-dependent insulinotropic polypeptide receptor: A potential therapeutic target for insulin dysregulation.Prolonged hyperinsulinemia affects metabolic signal transduction markers in a tissue specific manner.Histological and morphometric lesions in the pre-clinical, developmental phase of insulin-induced laminitis in Standardbred horses.The diagnosis of equine insulin dysregulation.Persistent digital hyperthermia over a 48 h period does not induce laminitis in horses.The impact of prolonged hyperinsulinaemia on glucose transport in equine skeletal muscle and digital lamellae.AICAR administration affects glucose metabolism by upregulating the novel glucose transporter, GLUT8, in equine skeletal muscle.Nutritional analysis of gastric contents and body condition score at a single time point in feral horses in Australia.Equine hyperinsulinemia: investigation of the enteroinsular axis during insulin dysregulation.The oral glucose test predicts laminitis risk in ponies fed a diet high in nonstructural carbohydrates.Equine glucagon-like peptide-1 receptor physiology.Toll-like receptor and pro-inflammatory cytokine expression during prolonged hyperinsulinaemia in horses: implications for laminitis.Glucagon-like peptide-2: A potential role in equine insulin dysregulation.The repeatability of an oral glucose test in ponies.The developmental and acute phases of insulin-induced laminitis involve minimal metalloproteinase activity.Sweet taste receptor inhibitors: Potential treatment for equine insulin dysregulation.The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated poniesEquine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine GroupDistances travelled by feral horses in ‘outback’ AustraliaInsulin and incretin responses to grazing in insulin-dysregulated and healthy poniesIncidence and risk factors for recurrence of endocrinopathic laminitis in horsesThe efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in poniesPhenotypic, hormonal, and clinical characteristics of equine endocrinopathic laminitisA "modified Obel" method for the severity scoring of (endocrinopathic) equine laminitis.Morphometry and abnormalities of the feet of Kaimanawa feral horses in New ZealandEvaluation of primary epidermal lamellar density in the forefeet of near-term fetal Australian feral and domesticated horsesContinuous intravenous infusion of glucose induces endogenous hyperinsulinaemia and lamellar histopathology in Standardbred horsesAdaption of horses to a novel dynamic feeding system: movement and behavioural responsesReining in equine metabolic syndrome: a gluttony of challengesThe feral horse foot. Part A: observational study of the effect of environment on the morphometrics of the feet of 100 Australian feral horsesThe effect of diet change and insulin dysregulation on the faecal microbiome of poniesThe effect of different grazing conditions on the insulin and incretin response to the oral glucose test in poniesScience in brief: Progress in endocrinopathic laminitis research: Have we got a foothold?Characterization of insulin and IGF-1 receptor binding in equine liver and lamellar tissue: implications for endocrinopathic laminitisUltrastructural examination of basement membrane pathology in horses with insulin-induced laminitisAn investigation of the equine epidermal growth factor system during hyperinsulinemic laminitisThe cresty neck score is an independent predictor of insulin dysregulation in ponies
P50
Q33928779-FAB9AD18-61C4-41EB-AEF3-C39F164C3438Q37275194-C7602C0F-2904-48FF-9865-E7DCE599C763Q37779144-023695A8-631A-4B93-872F-A646CE04778BQ38372992-2A051FD4-35B0-4DD5-99FA-8225F72FBBF2Q38382637-B132691D-65E4-42A8-841D-033B5440A6F0Q38401719-FEBB8064-40E7-47BA-97D3-19150E638190Q39329444-7B77D804-F8D3-4619-B92D-F93B1D579B5AQ40004287-5D506B57-E486-487E-A0CF-369839C7E56EQ40205322-8D74083B-62E7-4090-BF71-93B7871E4066Q40792299-7023C52B-79CB-4639-80DA-49A9EBB937C9Q43659341-D9F85925-3F8A-42AF-A53E-74E52DFDC6E1Q46644422-DDA82E0F-5D9C-421B-8898-38A25BF57F98Q47598118-BAEAABE1-61E2-4457-B10F-0FBE65B830C6Q48500262-1C7B45D7-405A-4C62-96C0-738F8AD24D89Q50708722-F1242F61-9C99-4ED7-982E-2175336E7F3BQ51246063-40D6F97C-FEAF-4A02-A965-EDBFFBED6C25Q51399417-E76FEE54-33E9-459E-8497-8E3EF4A77D8AQ51888363-C68EB481-19EF-4C0B-AD24-ED97D16E15CCQ55457762-E5D05004-061D-4CFC-9D06-DE2BBD92C3D9Q58744305-F1D5DC42-024F-463B-838F-FAA4C4B10FF3Q59761120-37AFC00F-0446-446E-A78D-48E3991E4A04Q60895270-D5EAED1B-3382-4BEC-8B43-6B51DBE511C0Q61453913-571CCD1E-DEAA-4C46-AD12-C0242A6E6057Q64060176-9E5CBF1D-9BBB-408B-8EB2-8DC2A558D1AAQ64099423-E4309EE8-B049-48A8-8B99-FE2C1BE62089Q64263558-BCAA7748-123B-4990-9015-37CB1F7A6D23Q64897866-EE316588-E075-4632-B2C6-F586ACE5ADA7Q84076514-11B24B42-7153-4E0D-BC47-1F628746CE2DQ84506593-7B3A52B0-38A3-45A7-8B99-DC0416FF656EQ84843716-1509C064-8C6D-4A8C-891E-410829868C55Q85631272-76331F24-D574-4626-A850-0CEB1D3BB339Q85922495-64DC903E-5B30-4804-84D3-06C6681C9E44Q85975338-597A431D-6E90-48B5-BCC4-392C9DC21FF7Q89881860-C1739AC1-9E30-4A0F-89E9-8E3DA9C95066Q90751467-A6F38AFA-958E-437D-A5D3-8B3892D0B821Q91366439-94BB408C-B499-4541-A5ED-F08867027981Q91387072-6ECA7C9D-248F-4353-A95F-C022F7B9E41BQ91678329-2DEFE2A7-96D2-45D0-98C0-092EAD9E9351Q91722258-5D6AA526-A2A7-4CAB-A9A8-AAB5633EF7DFQ92146983-2F47CB8C-DD8D-4E8A-9997-CFAE15241647
P50
description
researcher ORCID ID = 0000-0001-7922-3642
@en
wetenschapper
@nl
name
Melody Anne de Laat
@ast
Melody Anne de Laat
@en
Melody Anne de Laat
@es
Melody Anne de Laat
@nl
type
label
Melody Anne de Laat
@ast
Melody Anne de Laat
@en
Melody Anne de Laat
@es
Melody Anne de Laat
@nl
prefLabel
Melody Anne de Laat
@ast
Melody Anne de Laat
@en
Melody Anne de Laat
@es
Melody Anne de Laat
@nl
P106
P1153
36025195000
P31
P496
0000-0001-7922-3642